髓系肿瘤中表观遗传靶分子与治疗的演变格局:聚焦急性髓系白血病与骨髓增殖性肿瘤
该综述回顾了髓系肿瘤中基于染色质的疾病机制,包括DNA甲基化、染色质调控复合物和组蛋白修饰,并总结了已获批或正在研究中的表观遗传靶向治疗。测序研究显示超过60%的急性髓系白血病病例携带表观遗传调控因子的致病突变。多种靶向表观遗传机制的药物已获批用于治疗髓系肿瘤,更多药物正在临床试验和临床前研究中。
要点
- 超过60%的急性髓系白血病病例携带表观遗传调控因子的致病突变。
- 染色质调控因子常控制疾病特异性转录程序,是有吸引力的治疗靶点。
- 多种靶向表观遗传机制的药物已获批用于髓系肿瘤,更多正在研究中。
核心结论
- 表观遗传失调是髓系肿瘤的共同疾病机制,针对染色质致癌机制的药物已获批用于治疗髓系肿瘤,更多药物正在临床试验和临床前研究中。
研究设计与样本
- 综述,回顾髓系肿瘤中基于染色质的疾病机制及已获批或研究中的表观遗传靶向治疗。
主要发现
- 测序研究显示超过60%的急性髓系白血病病例携带表观遗传调控因子的致病突变。
- 染色质调控因子常控制疾病特异性转录程序,尤其在髓系肿瘤中是有吸引力的治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Research on myeloid neoplasms, a field that has been driving scientific advances in cancer for over 50 years, has yielded many discoveries that have fundamentally reshaped our understanding of cancer biology. These insights, often the product of leukemia research, have been instrumental in developing more mechanism-based treatments in the early 2000s [1]. Recognizing epigenetic dysregulation as a common disease mechanism in myeloid cancers has been groundbreaking regarding recent treatment developments that exploit chromatin-based oncogenic mechanisms. In the case of acute myeloid leukemia (AML), sequencing studies aimed at assessing the complement of genetic alterations demonstrated that more than 60% of AML cases harbored disease-driving mutations in epigenetic regulators. This high prevalence underscores the importance of epigenetic dysregulation in AML pathogenesis [2, 3]. Chromatin regulators commonly control disease-specific transcriptional programs, making them attractive therapeutic targets to manipulate neoplastic gene expression programs, particularly in myeloid neoplasms. Several drugs targeting epigenetic mechanisms and exploiting myeloid disease-specific dependencies have recently been approved for treating myeloid neoplasms. Many additional drugs are currently being investigated in clinical trials, and numerous new compound developments are being studied in preclinical studies. This manuscript will review (1) chromatin-based disease mechanisms, such as DNA methylation, chromatin regulatory complexes, and histone modifications, currently investigated for therapeutic exploitation in myeloid malignancies, and (2) therapeutic developments already approved or investigated for treating these diseases.
引用
- Kühn MWM, Pemmaraju N, Heidel FH, et al. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms. Leukemia. 2025. PMID: 40374809. doi:10.1038/s41375-025-02639-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。